Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.

Key words major depressive disorder levomilnacipran antidepressant serotonin and norepinephrine reuptake inhibitor response remission Improvements in MADRS total score were also significantly greater with levomilnacipran ER than placebo in the overall pooled population and in all patient subgroups, except for those with MDD duration <2 years or current episode duration ≥12 months ( Table 3 ), which showed a numerical advantage for levomilnacipran ER but did not reach statistical significance.

also in 111,027 other papers